f) indukce ovulace při in vitro fertilizaci pouze na základě předchozího schválení revizním lékařem.
| 318.1 | L02AE01 | buserelin | parent. | 1 | MG | 253,00 | K/P |
|
| 318.2 | L02AE01 | buserelin (depotní lékové formy aplikované 1x měsíčně) | parent. | 1 | MG | 1719,80 | K/P |
| 75018 | SUPREFACT DEPOT | imp 1ks=2x3.15mg+ap | AVT | D |
| 318.3 | L02AE01 | buserelin (depotní lékové formy aplikované 1x za tři měsíce) | parent. | 1 | MG | 1576,70 | K/P |
| 66042 | SUPREFACT DEPOT 3 MĚSÍCE | imp 1x9.45mg=3xstl | AVT | D |
| 318.4 | L02AE02 | leuprorelin | parent. | 1 | MG | 253,00 | K/P |
|
| 318.5 | L02AE02 | leuprorelin (depotní lékové formy aplikované 1x měsíčně) | parent. | 1 | MG | 1522,80 | K/P |
|
| 318.6 | L02AE02 | leuprorelin (depotní lékové formy aplikované 1x za tři měsíce) | parent. | 1 | MG | 1324,50 | K/P |
|
| 318.7 | L02AE03 | goserelin (depotní lékové formy aplikované 1x měsíčně) | parent. | 1 | MG | 1522,80 | K/P |
|
| 318.8 | L02AE03 | goserelin (depotní lékové formy aplikované 1x za tři měsíce) | parent. | 1 | MG | 1379,60 | K/P |
|
| 318.9 | L02AE04 | triptorelin | parent. | 1 | DF | 251,89 | K/P |
| 58623 | DIPHERELINE 0.1 MG | inj psu Iqf 7x0.1 mg | IAA | F |
| 318.10 | L02AE04 | triptorelin (depotní lékové formy aplikované 1x měsíčně) | parent. | 1 | MG | 1516,13 | K/P |
| 01656 | DIPHERELINE S.R. 3 MG | inj psu Iqf 1x3mg | IAA | F |
| 318.11 | L02AE04 | triptorelin (depotní lékové formy aplikované 1x za tři měsíce) | parent. | 1 | MG | 1324,50 | K/P |
| 319 | L02BA | antiestrogeny | p.o. | |
|---|
| 319.1 | L02BA01 | tamoxifen (do 20 mg v 1 tabletě včetně) | p.o. | 20 | MG | 6,00 | |
| 64810 | NOLVADEX D | por tbl flm 30x20mg | AZC | GB |
| 67039 | TAMIFEN 10 | por tbl nob 30x10mg | MOE | CY |
| 10703 | TAMIFEN 10 | por tbl nob100x10mg | MOE | CY |
| 44056 | TAMOXIFEN EBEWE 10 MG | por tbl nob30x10mg | EBP | A |
| 58701 | TAMOXIFEN EBEWE 10 MG | por tblnob100x10mg | EBP | A |
| 44057 | TAMOXIFEN EBEWE 20 MG | por tbl nob30x20mg | EBP | A |
| 58702 | TAMOXIFEN EBEWE 20 MG | por tblnob100x20mg | EBP | A |
| 88392 | TAMOXIFEN LACHEMA 10 | tbl 100x10mg | PVL | CZ |
| 12446 | TAMOXIFEN-RATIOPHARM 10 | tbl 100x10mg | MCK | D |
| 319.2 | L02BA01 | tamoxifen (nad 20 mg v 1 tabletě) | p.o. | 20 | MG | 4,40 | |
| 44058 | TAMOXIFEN EBEWE 30 MG | por tbl nob30x30mg | EBP | A |
| 44059 | TAMOXIFEN EBEWE 40 MG | por tbl nob30x40mg | EBP | A |
| 320 | L02BB | antiandrogeny | p.o. | |
|---|
| 320.1 | L02BB01 | flutamid | p.o. | 0,75 | GM | 81,21 | L/ONK,URN,SEX,END |
| 54521 | ANDRAXAN | tbl obd 100x250mg | MCI | CZ |
| 58741 | APO-FLUTAMIDE | tbl obd 100x250mg | APT | CND |
| 83392 | FLUCINOM | por tblnob100x250mg | SCH | B |
| 31736 | FLUTAPLEX | portblnob100x250mg | PHM | NL |
| 47084 | PROSTANDRIL | tbl 100x250mg | PLI | CHO |
| 320.2 | L02BB02 | nilutamid | p.o. | 0,3 | GM | 162,42 | L/ONK,URN,SEX |
| 93259 | ANANDRON 150 MG | tbl 30x150mg | LBU | F |
| 320.3 | L02BB03 | bicalutamid | p.o. | 50 | MG | 107,14 | L/ONK,URN,SEX |
| 321 | L02BG | inhibitory tvorby steroidních hormonů | p.o. | |
|---|
| 321.1 | L02BG01 | aminogluthetimid | p.o. | 1 | GM | 62,45 | L/ONK,END |
|
| 321.2 | L02BG03 | anastrozol | p.o. | 1 | MG | 160,00 | X |
|
| 321.3 | L02BG04 | letrozol | p.o. | 2,5 | MG | 160,00 | X |
| 321.4 | L02BG06 | exemestan | p.o. | 25 | MG | 160,00 | X |
| 322 | L02BG | inhibitory tvorby steroidních hormonů | parent. | |
|---|
| 322.1 | L02BG02 | formestan | parent. | 18 | MG | 233,77 | X |
| 92361 | LENTARON DEPOT 250MG I.M. | inj sic 1x250mg+sol | NPA | CH |
| 323.1 | L03AA02 | filgrastim | parent. | 1 | MG | 9548,00 | X |
|
| 323.2 | L03AA03 | molgramostim (do 0,3 mgG včetně v jedné ampuli) | parent. | 1 | MG | 13613,27 | X |
|
| 323.3 | L03AA03 | molgramostim (nad 0,3 mg v jedné ampuli) | parent. | 1 | MG | 11843,67 | X |
|
| 323.4 | L03AA10 | lenograstim | parent. | 1 | MG | 12477,40 | X |
|
| 323.5 | L03AB01 | interferon alfa natural | parent. | 1 | MU | 230,63 | X |
|
| 323.6 | L03AB03 | interferon gamma | parent. | 1 | MU | 1531,33 | X |
|
| 323.7 | L03AB04 | interferon alfa-2a - aplikční forma „pera“ | parent. | 1 | MU | 230,63 | X |
| 54402 | ROFERON-A 18 MIU/0.6ML | inj 3x0.6ml/18mu | HLR | CH |
| 323.8 | L03AB04 | interferon alfa-2a do 10 MU v 1 ampuli vč. - jiné aplikační formy | parent. | 1 | MU | 230,63 | X |
| 10647 | ROFERON-A 6 MIU/0.5 ML | sol inj1x6miu/0,5ml | HLR | CH |
| 10648 | ROFERON-A 6 MIU/0.5 ML | sol inj5x6miu/0,5ml | HLR | CH |
| 10664 | ROFERON-A 9 MIU/0.5 ML | sol inj1x9miu/0,5ml | HLR | CH |
| 10668 | ROFERON-A 9 MIU/0.5 ML | sol inj5x9miu/0,5ml | HLR | CH |
| 323.9 | L03AB04 | interferon alfa-2a nad 10 MU v 1 ampuli vč. - jiné aplikační formy | parent. | 1 | MU | 213,15 | X |
|
| 323.10 | L03AB05 | interferon alfa-2b - aplikční forma „pera“ | parent. | 1 | MU | 230,63 | X |
| 32573 | INTRONA 18 MIU REDIPEN | inj sol 1.2ml/6x3mu | SCH | IRL |
| 32572 | INTRONA 30 MIU REDIPEN | inj sol 1.2ml/6x5mu | SCH | IRL |
| 32574 | INTRONA 60 MIU REDIPEN | inj sol1.2ml/6x10mu | SCH | IRL |
| 323.11 | L03AB05 | interferon alfa-2b do 10 MU v 1 ampuli včetně - jiné aplikační formy | parent. | 1 | MU | 230,63 | X |
| 32575 | INTRONA 10 MIU | inj sol 1ml/10mu | SCH | IRL |
| 323.12 | L03AB05 | interferon alfa-2b nad 10 MU v 1 ampuli - jiné aplikační formy | parent. | 1 | MU | 213,15 | X |
|
| 323.13 | L03AB06 | interferon alfa-n 1 do 9MU v 1 ampuli včetně | parent. | 1 | MU | 230,63 | X |
|
| 323.14 | L03AB06 | interferon alfa-n1 více než 9MU v 1 ampuli | parent. | 1 | MU | 213,15 | X |
|
| 323.15 | L03AB07 | interferon beta - 1a | parent. | 1 | MU | 409,37 | X |
| 01795 | REBIF 44 | inj 12x0.5ml/44rg | IFB | I |
| 01793 | REBIF 44 | inj 1x0.5ml/44rg | IFB | I |
| 01794 | REBIF 44 | inj 3x0.5ml/44rg | IFB | I |
| 323.16 | L03AB07 | interferon beta - 1a výhradně pro intramuskulární podání | parent. | 1 | DF | 5932,25 | X |
| 06241 | AVONEX | inj sic 4x30rg+solv | BHF | NL |
| 323.17 | L03AB08 | interferon beta - 1 b | parent. | 1 | MU | 276,80 | X |
|
| 323.18 | L03AB09 | interferon alfacon - 1 | parent. | 1 | MU | 230,63 | X |
|
| 323.19 | L03AB10 | peginterferon alfa 2-b | parent. | 1 | RG | 72,83 | X |
| 10132 | PEGINTRON 50 | inj pso Iqf 1x50rg | SCH | IRL |
| 10187 | PEGINTRON 80 | inj pso Iqf 1x80rg | SCH | IRL |
| 95705 | PEGINTRON REDIPEN 100 MCG | inj pso Iqf 1x100rg | SCH | IRL |
| 95706 | PEGINTRON REDIPEN 100 MCG | inj pso Iqf 4x100rg | SCH | IRL |
| 95709 | PEGINTRON REDIPEN 120 MCG | inj pso Iqf 1x120rg | SCH | IRL |
| 95710 | PEGINTRON REDIPEN 120 MCG | inj pso Iqf 4x120rg | SCH | IRL |
| 95707 | PEGINTRON REDIPEN 150 MCG | inj pso Iqf 1x150rg | SCH | IRL |
| 95708 | PEGINTRON REDIPEN 150 MCG | inj pso Iqf 4x150rg | SCH | IRL |
| 95703 | PEGINTRON REDIPEN 80 MCG | inj pso Iqf 1x80rg | SCH | IRL |
| 95704 | PEGINTRON REDIPEN 80 MCG | inj pso Iqf 4x80rg | SCH | IRL |
| 323.20 | L03AB11 | peginterferon alfa 2-a | parent. | 1 | RG | 47,40 | X |
|
| 323.21 | L03AC01 | aldesleukin | parent. | 1 | MG | 7517,20 | X |
| 324 | L03AX | ostatní imunostimulační léčiva | lok., p.o. | |
|---|
| 324.1 | L03AX | směs bakteriálních lyzátů | p.o. | 1 | BA | 60% | |
|
| 324.2 | L03AX | směs bakteriálních lyzátů | lok. | 1 | BA | 60% | L/ALG,ORL |
|
| 324.3 | L03AX | dialyzát vepřových leukocytů | p.o. | 1 | BA | 60% | L/ALG,IMU |
|
| 324.4 | L03AX | vaccin. staphyl. phagolys. | lok. | 1 | ML | 36,51 | L/ALG,ORL |
| 325 | L03AX | ostatní imunostimulační léčiva | parent. | |
|---|
| 325.1 | L03AX03 | BCG vakcína | parent. | 1 | MG | 37,00 | O/ONK,URN |
| 53968 | IMMUCYST | inj sic 1x81mg+solv | APZ | CND |
| 68908 | IMMUCYST | inj sic 3x27mg+solv | APZ | CND |
| 325.2 | L03AX | dialyzát lidských leukocytů | parent. | 1 | DF | 844,00 | P |